The role of adjuvant endocrine treatment in ER+, PR−, HER2− early breast cancer: a retrospective study of real-world data

Miaochun Zhong, Xiaoqiu Ren, Wenjie Xia, Yangyang Qian, Kewang Sun, Jun Wu · 2024

Read The role of adjuvant endocrine treatment in ER+, PR−, HER2− early breast cancer: a retrospective study of real-world data by Miaochun Zhong, Xiaoqiu Ren, Wenjie Xia, Yangyang Qian, Kewang Sun, Jun Wu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11530533.txt.

Description

Purpose: Estrogen receptor-positive (ER+), progesterone receptor-negative (PR-) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) often developed resistance to endocrine treatment (ET). We aimed to explore (1) the different clinicopathological features between ER+/PR+/HER2- and ER+/PR-/HER2- BC, and (2) whether ER+/PR-/HER2- early BC patients could benefit from adjuvant ET.

Catalog record

CREATORMiaochun Zhong, Xiaoqiu Ren, Wenjie Xia, Yangyang Qian, Kewang Sun, Jun Wu
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE23 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11530533

Browse the full library · About the Tower of Babel